A Phase I/II Multi-Center, Open Label Study of TKI258 [dovitinib] Administered Orally on an Intermittent Schedule in Adult Patients With Advanced or Metastatic Renal Cell Cancer (RCC).

Trial Profile

A Phase I/II Multi-Center, Open Label Study of TKI258 [dovitinib] Administered Orally on an Intermittent Schedule in Adult Patients With Advanced or Metastatic Renal Cell Cancer (RCC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Apr 2015

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004045).
    • 26 May 2012 Planned number of patients changed from 91 to 110 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top